Business news for the stock market
QLUPOD AG: QluPod expands Advisory Board with Prof. Dr. Jalid Sehouli from Charité Universitätsmedizin Berlin
Herisau (pta016/27.02.2024/10:19 UTC+1)
QluPod expands its expertise: Prof. Dr. med. Dr. h.c. Jalid Sehouli from
Charité Universitätsmedizin Berlin joins the Advisory Board
QluPod AG, a successful start-up in the field of telemedicine, announces the addition of Prof. Dr. Jalid Sehouli from the renowned Charité-Universitätsmedizin clinic in Berlin to its Advisory Board. Prof. Dr. Jalid Sehouli is Director of the Clinic for Gynaecology and Oncological Surgery at the Charité Campus Virchow-Klinikum and Head of the European Centre of Excellence and Gynaecological Tumour Centre for Ovarian Cancer (EKZE).
A recognised expert, Prof. Dr. Jalid Sehouli enjoys an excellent reputation as a gynaecologist specialising in women's cancers. His expertise spans various medical disciplines, including leading several studies on targeted therapies with the aim of significantly improving patient care and quality of life. This approach fits perfectly with QluPod AG's mission to offer consumers a better life through innovative healthcare technology. To this end, QluPod has developed a wearable health monitor that allows users to measure six vital signs simultaneously and transmit them to their doctor.
The decision to add Prof. Dr. Jalid Sehouli to the Advisory Board represents a milestone for QluPod. The expansion emphasises and strengthens the company's connection with outstanding medical expertise for a scientifically sound and reliable evaluation of measured health data. At the same time, the connection with Prof. Dr. Jalid Sehouli helps to realise the vision of further developing various areas of telemedicine and making them available to as many patients, clinics, doctors and medical care providers as possible. Prof. Dr. Jalid Sehouli is supporting the QluPod team on this journey with his experience and extensive medical knowledge.
In addition to his position as Director of the Department of Gynaecology, Prof. Dr. Jalid Sehouli holds a professorship (full professorship) in gynaecology for life at the Charité - Universitätsmedizin Berlin. His membership of numerous medical societies for obstetrics, gynaecology and cancer research underlines his close ties to the scientific community. This enables Prof. Dr. Jalid Sehouli to make a decisive contribution to future developments and innovations and the dissemination of the QluPod Health Monitor and its proprietary app.
The collaboration with Prof. Dr. Jalid Sehouli strengthens QluPod's scientific expertise and helps to continuously improve the applications. "The appointment of Prof. Dr. Jalid Sehouli as a new member of our Advisory Board is an important step in the development of QluPod and underlines our sustained commitment to excellence in medical care," emphasises Nikola Trajanov, interim CEO and partner of QluPod. Aidan Burley, Head of Marketing and Sales, adds: "This expansion strengthens our position in the telemedicine sector and as a provider of innovative health tech solutions.
The entire QluPod team is thrilled to have Prof. Dr. Jalid Sehouli on board and looks forward to keeping you up to date on the developments and innovations of the QluPod App and QluPod's services!
About QluPod:
QluPod AG is a start-up company in the field of telemedicine and develops innovative solutions to make patient care efficient and cost-effective. With the QluPod device and the associated software, the company is endeavouring to shape the future of healthcare.
The offering is aimed at hospitals, care facilities, medical professionals and private individuals who want to monitor their health independently.
For more information about QluPod AG and our products, please visit our website at www.qlupod.com.
Disclaimer:
This publication constitutes neither an offer to sell nor a solicitation to buy securities.
Insofar as this document contains forward-looking statements, these do not represent
facts and are characterised by the words "expect", "believe", "estimate", "intend",
"aim", "assume" and similar expressions. These statements express the intentions,
opinions or current expectations and assumptions of QluPod AG and are based on
current plans, estimates and forecasts which QluPod AG has made to the best of its
knowledge, but do not claim to be correct in the future. Forward-looking statements are
subject to risks and uncertainties that are generally difficult to predict and are usually
beyond the control of QluPod AG. It should be noted that actual events or developments
may differ materially from the events and developments expressed or implied by such
forward-looking statements.
(end)
| Emitter: |
QLUPOD AG Bahnhofstrasse 23 9100 Herisau Switzerland |
|
|---|---|---|
| Contact Person: | Investor Relations | |
| Phone: | +41 71 510 05 45 | |
| E-Mail: | ir@qlupod.com | |
| Website: | qlupod.com | |
| ISIN(s): | CH1222316429 (Share) | |
| Stock Exchange(s): | - | |
| Other Stock Exchanges: | Regelmaessige Kursfeststellung Schweiz |